Skip to main content

European network on Myalgic encephalomyelitis/Chronic fatigue syndrome (EUROMENE)

Project/agreement No.
COST aktivitāte Nr. 15111
Project funding
431 268.20 EUR
Project realization
21.04.2016. - 20.04.2021.


Establish a sustainable, integrated European researchers’ network in the field of myalgic encephalomyelitis/chronic fatigue syndrome to address the research issues of unknown aetiology, clinical variability, lack of diagnostic biomarkers and limited treatment options that have significant negative socio-economic impact on national economy.


COST (European Cooperation in Science and Technology) activity  European Network on Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome,   (EUROMENE)  was established in 2016.  Initially 11 countries of the European Union (Belgium, Bulgaria, France, Germany, Italy, Latvia, Norway, Romania, Serbia, Spain, United Kingdom) and Belarus took part in this activity.
RSU Microbiology and Virology Institute (MVI), as the project’s initiator, represents Latvia in COST activity and has been approved as the project coordinator and the beneficiary of financing. Professor M. Murovska, director of  Institute of Microbiology and Virology, was elected as the chairperson of the COST  activity 15111 EUROMENE. 
Chronic fatigue syndrome is a complicated disease characterised by chronic fatigue, muscle pain, weakness, issues related to memory and concentration. Implementation of EUROMENE project will result in reflection of CFS possible treatment methods, enabling patients to recover faster from this disease.

The main activities of the project

  • COST Action Management Committee meeting,
  • Training Schools, Summer Schools
  • Short Term Scientific Missions (STSM),
  • Conference Grants,
  • participation in international conferences,
  • COST Action Dissemination.

Project implementation

The first meeting of the EUROMENE Cost Action CA 1511 on 21st April 2016, Brussels, Belgium

On 21st April 2016, the first meeting of the EUROMENE Cost Action CA 1511 was held in Brussels. The first part of the meeting provided general information on the cost action mechanisms and implementation. The second part of the day was dedicate to take a number of important decisions: 

  • The Rīga Stradiņš University was elected as the Grant Holder Institution;
  • the Chair and Vice Chair of EUROMENE project were elected:
    • Chair: Modra Murovska (Latvia);
    • Vice Chair:  Eliana Lacerda (United Kingdom). 
  • Leaders and Vice-leaders for the following Working Groups (WG) were elected:
    • WG1 on epidemiology – Leader Jesus Castro-Marrero, Vice-leader Slobodan Sekulic (Serbia),
    • WG2 on biomarkers – Leader Carmen Scheibenbogen (Germany), Vice-leader Enrica Capelli (Italy),
    • WG3 on socio-economics – Leader Derek Pheby (UK), Vice-leader Julian Blanco (Spain),
    • WG4 on clinical research enablers and diagnostic criteria – Leader Elin Bolle Strand (Norway), Vice-leader Jerome Authier (France),
    • WG5 on conferences, seminars, training schools – Leader Evelina Shikova-Lekova (Bulgaria),
    • WG6 on dissemination and exploitation, patient involvement, digitalization – Leader Lorenzo Lorusso (Italy), Vice-leader Anne Marit Mengshoel (Norway),
    • STSM coordination – Coordinator Els Tobback (Belgium), Vice-coordinator Carmen Adella Sirbu (Romania).
  • Work and budget plan for the first Grant Period was approved
New member States 2016-2018

2016- New Member States
In 2016 from June to December 4 EU countries have joined the network: Denmark, Finland, Ireland, Sweden.
2017 - Enlargement of the Euromene network
In 2017, joined 3 EU countries - Portugal, Greece, the Netherlands.
2018 - Enlargement of the Euromene network
In 2018, joined 3 EU countries - Austria, Poland, Slovenia.

Conference "Common strategy on research of ME/CFS", March 12-13, 2020

On 12 & 13 March 2020 was held in  Rīga Stradiņš University the final conference, Common Strategy on Research of ME/CFS. The  conference is part of the COST Action project “European Network on Myalgic Encephalomyelitys/Chronic Fatigue Syndrome“(EUROMENE, No CA15111).

The conference of the COST action CA 15111 was opened by Ilmārs Stonāns, the head of RSU Science Strategy and COST Chair Prof. Modra Murovska.
Overall, the conference both in person and online attended by about 50 researchers and other interested persons from 14 countries - Australia, Belarus, Bulgaria, Denmark, Greece, Latvian, Great Britain, the Netherlands, Poland, Romania, Finland, Spain, Serbia, Germany.
The scientific programme covered the research agenda of COST Action and sessions reflected the following topics:

  • ME/CFS epidemiology,
  • ME/CFS biomarkers,
  • ME/CFS socio-economics,
  • ME/CFS clinical research.

Book of abstracts

Information posted on 16.03.2020


Extended project implementation

Due to the COVID-19 pandemic, which disrupted the final conference of the project this year on March 12-13, the COST association extended the project implementation for 6 months, it is until October 20, 2020 to achieve the project results.

Therefore, this year on September 29-30, managment Committee and working group meeting will be held at Riga Stradiņš University. MC meeting will analyse participating state activities and discuss and approve concrete follow-up plans and post-Action strategy  to ensure further development of integrated European researchers network.

At the same time, the members of  CA 15111 as experienced clinicals and researchers have started investigationg different conditions related to COVID-19 morbidity and SARS-CoV-2 infection during COVID-19 epidemics. Therefore, issues related COVID-19 will also be addressed during the MC meeting.

Information posted on 07.09.202